Enhanced Oral Bioavailability of Piroxicam in Rats by Hyaluronate Microspheres

REFERENCES

• Alkrad J. A., Mrestani Y., Neubert R. H. The release profiles of intact and enzymatically digested hyaluronic acid from semisolid formulations using multi-layer membrane system. Eur. J. Pharm. Biopharm. 2003; 56(1)37–41
   PubMed Web of Science ®Google Scholar
• Amidon G. L., Lennernäs H., Shah V. P., Crison J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995; 12: 413–420
   PubMed Web of Science ®Google Scholar
• Attama A. A., Mpamaugo V. E. Pharmacodynamics of piroxicam from self-emulsifying lipospheres formulated with homolipids extracted from Capra hircus. Drug Deliv. 2006; 13(2)133–137
   PubMed Web of Science ®Google Scholar
• Barzegar-Jalali M., Maleki N., Garjani A., Khandar A. A., Haji-Hosseinloo M., Jabbari R., Dastmalchi S. Enhancement of dissolution rate and anti-inflammatory effects of piroxicam using solvent deposition technique. Drug Dev. Ind. Pharm. 2002; 28(6)681–686
   PubMed Web of Science ®Google Scholar
• Bhattacharyya M., Basu S. K., Gupta B. K., Ghosal S. K., Mandal S. C., Chattaraj S. C. Formulation and in vitro-in vivo characterization of solid dispersions of piroxicam. Drug Dev. Ind. Pharm. 1993; 19: 29–35
   Web of Science ®Google Scholar
• Cleland J. L., Jones A. J. Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres. Pharm. Res. 1996; 13(10)1464–1475
   PubMed Web of Science ®Google Scholar
• Dadashzadeh S., Vali A. M., Rezagholi N. LC determination of piroxicam in human plasma. J. Pharmaceut. Biomed. 2002; 28: 1201–1204
   PubMed Web of Science ®Google Scholar
• Fernández M., Margarit M. V., Rodríguez I. C., Crezo A. Dissolution kinetics of piroxicam in solid dispersions with polyethylene glycol 4000. Int. J. Pharm. 1993; 98: 29–35
   Web of Science ®Google Scholar
• Fernandez-Carballido A., Herrero-Vanrell R., Molina-Martinez I. T., Pastoriza P. Biodegradable ibuprofen-loaded PLGA microspheres for intraarticular administration. Effect of Labrafil addition on release in vitro. Int. J. Pharm. 2004; 279: 33–41
   PubMed Web of Science ®Google Scholar
• Fraser J. R. E., Laurent T. C., Laurent U. B. G. Hyaluronan: its nature, distribution, functions and turnover. J. Intern. Med. 1997; 242: 27–33
   PubMed Web of Science ®Google Scholar
• Goa K. L., Benfield P. Hyaluronic acid—a review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound-healing. Drugs 1994; 47(3)536–566
   PubMed Web of Science ®Google Scholar
• Jederstrom G., Andersson A., Grasjo J., Sjoholm I. Formulating insulin for oral administration: preparation of hyaluronan-insulin complex. Pharm. Res. 2004; 21(11)2040–2047
   PubMed Web of Science ®Google Scholar
• Jiang H., Wang Y., Huang Q., Li Y., Xu C., Zhu K., Chen W. Biodegradable hyaluronic acid/n-carboxyethyl chitosan/protein ternary complexes as implantable carriers for controlled protein release. Macromol. Biosci. 2005; 5(12)1226–1233
   PubMed Web of Science ®Google Scholar
• Jiang W., Schwendeman S. P. Stabilization and controlled release of bovine serum albumin encapsulated in poly (D, L-lactide) and poly (ethylene glycol) microsphere blends. Pharm. Res. 2001; 18(6)878–885
   PubMed Web of Science ®Google Scholar
• Jouon N., Rinaudo M., Milas M., Desbrieres J. Hydration of hyaluronic-acid as a function of the counterion type and relativehumidity. Carbohydrate Polym 1995; 26(1)69–73
   Web of Science ®Google Scholar
• Jug M., Becirevic-Lacan M. Influence of hydroxypropyl-β-cyclodextrin complexation on piroxicam release from buccoadhesive tablets. Eur. J. Pharm. Sci. 2004; 21: 251–260
   PubMed Web of Science ®Google Scholar
• Jug M., Becirevic-Lacan M., Cetina-Cizmek B., Horvat M. Hydroxypropyl methylcellulose microspheres with piroxicam and piroxicam-hydroxypropyl-β-cyclodextrin inclusion complex. Pharmazie 2004; 59(9)686–691
   PubMed Web of Science ®Google Scholar
• Kim C. K., Choi J. Y., Yoon Y. S., Gong J. P., Choi H. G., Kong J. Y., Lee B. J. Preparation and evaluation of dry elixir for the enhancement of dissolution rate of poorly water-soluble drugs. Int. J. Pharm. 1994; 106: 25–32
   Web of Science ®Google Scholar
• Kim C. K., Yoon Y. S., Kong J. Y. Preparation and evaluation of flurbiprofen dry elixir as a novel dosage form using a spray-drying technique. Int. J. Pharm. 1995; 120: 21–31
   Web of Science ®Google Scholar
• Kimura E., Bersani-Amado C. A., Sudo L. S., Santos S. R. J., Oga S. Pharmacokinetic profile of piroxicam b-cyclodextrin in rat plasma and lymph. Gen. Pharmacol. 1997; 28: 695–698
   PubMedGoogle Scholar
• Lapcik L., De Smedt S., Demeester J., Chabrecek P. Hyaluronan: Preparation, structure, properties, and applications. Chem. Rev. 1998; 98(8)2663–2684
   PubMed Web of Science ®Google Scholar
• Laurent T. C., Laurent U. B. G., Fraser J. R. E. Functions of hyaluronan. Ann. Rheum. Dis. 1995; 54: 429–432
   PubMed Web of Science ®Google Scholar
• Lee S. W., Kim M. H., Kim C. K. Encapsulation of ethanol by spray drying technique: effects of sodium lauryl sulfate. Int. J. Pharm. 1999; 187: 193–198
   PubMed Web of Science ®Google Scholar
• Mallarde D., Boutignon F., Moine F., Barre E., David S., Touchet H., Ferruti P., Deghenghi R. PLGA-PEG microspheres of teverelix: influence of polymer type on microsphere characteristics and on teverelix in vitro release. Int. J. Pharm. 2003; 261: 69–80
   PubMed Web of Science ®Google Scholar
• Pan R. N., Chen J. H., Chen R. R. Enhancement of dissolution and bioavailability of piroxicam in solid dispersion systems. Drug Dev. Ind. Pharm. 2000; 26(9)989–994
   PubMed Web of Science ®Google Scholar
• Pollauf E. J., Kim K. K., Pack D. W. Small-molecule release from poly(D, L-lactide)/poly(D, L-lactide-co-glycolide) composite microparticles. J. Pharm. Sci. 2005; 94(9)2013–2022
   PubMed Web of Science ®Google Scholar
• Sallmann A. R. The history of diclofenac. Semin. Arthritis Rheum. 1985; 15: 57–60
   PubMed Web of Science ®Google Scholar
• Shin S. C., Cho C. W. Physicochemical characterizations of piroxicam-poloxamer solid dispersion. Pharm. Dev. Technol. 1997; 2(4)403–407
   PubMedGoogle Scholar
• www.toxicology.org/AI/FA/guidingprinciples. pdf Society of Toxicology (SOT) (1999). Guilding Priciples in the Use of Animals in Toxicology
   Google Scholar
• Tagliati C. A., Kimura E., Nothenberg M. S., Santos S. R. J. C., Oga S. Pharmacokinetic profile and adverse gastric effect of zinc-piroxicam in rats. Gen. Pharmacol. 1999; 13: 67–71
   Google Scholar
• Tantishaiyakul V., Kaewnopparat N., Ingkatawornwong S. Properties of solid dispersions of piroxicam in polyvinylpyrrolidones. Int. J. Pharm. 1999; 181: 143–151
   PubMed Web of Science ®Google Scholar
• Turley E. A., Roth S. Interactions between the carbohydrate chains of hyaluronate and chondroitin sulphate. Nature 1980; 283(5744)268–271
   PubMed Web of Science ®Google Scholar
• Verma M. M., Kumar M. T., Balasubramaniam J., Pandit J. K. Dissolution, bioavailability and ulcerogenic studies on piroxicam-nicotinamide solid dispersion formulations. Boll. Chim. Farm. 2003; 142(3)119–124
   PubMedGoogle Scholar
• Yuksel N., Karatas A., Ozkan Y., Savaser A., Ozkan S. A., Baykara T. Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 2003; 56: 453–459
   PubMed Web of Science ®Google Scholar